Sex hormone–binding globulin—A surrogate marker for the prothrombotic effects of combined oral contraceptives
- 29 February 2004
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 190 (2), 332-337
- https://doi.org/10.1016/s0002-9378(03)00950-5
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Venous thromboembolism amng new users of different oral contraceptives.The Lancet, 1999
- A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrelContraception, 1998
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997
- Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsInternational Journal of Gynecology & Obstetrics, 1996
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995
- Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptivesContraception, 1995
- Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrelContraception, 1993
- Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen bindingScandinavian Journal of Clinical and Laboratory Investigation, 1981